ApexOnco Front Page Recent articles 7 August 2025 Bristol takes its bispecific conjugate into lung cancer A second global pivotal trial will test iza-bren in the same NSCLC setting where patri-dxd failed. 7 August 2025 Arvinas rules out a solo vepdegestrant launch If Pfizer hands back the estrogen receptor degrader, Arvinas will seek a new partner. 10 April 2024 AACR 2024 – Medicenna looks for a cytokine renaissance After numerous IL-2 failures there are glimmers of hope for the group’s contender, MDNA11. 10 April 2024 Familiar targets with a twist First-in-human study initiations feature variations on well-trodden targets, plus a minor hiccup for OncoC4. 10 April 2024 AACR 2024 – Transgene gets a “vaccine” boost Early data with the group’s personalised project intrigue, but Transgene has a long road ahead. 10 April 2024 AACR 2024 – a first look at Astra’s ATM inhibitor One of the first human datasets concerning an ATM inhibitor shows glioblastoma’s intractability. 9 April 2024 AACR 2024 – Vincerx overreaches The company's comparison of its ADCs to Enhertu seems farfetched. 9 April 2024 AACR 2024 – Astra plays up PARP1 inhibition Selectively hitting PARP1 is meant to reduce toxicity, and arguably the Petra trial shows this. Load More Recent Quick take Most Popular